We aimed to investigate 3,5,3′-triiodothyroacetic acid (TRIAC) effects on intact and atrophic skin induced by glucocorticoids (GCs) in rats and the effects induced by nanoencapsulation. The effects of TRIAC and nanoencapsulated TRIAC were evaluated on intact and atrophic skin in TRIAC experiment and nanoencapsulated TRIAC experiment, respectively. Both experiments had two phases: phase I, cutaneous atrophy was induced; phase II, TRIAC or nanoencapsulated TRIAC was administrated. Our results showed that topical use of TRIAC with or without nanoencapsulation was able to reverse cutaneous atrophy. Nanoencapsulated TRIAC showed less systemic changes than TRIAC; therefore, it is possibly a safer drug for topical administration.
Effects of 3,5,3′-Triiodothyroacetic Acid, Nanoencapsulated or Not, on Intact and Atrophic Skin in Rats
Manuscript received March 18, 2014; final manuscript received September 26, 2014; published online October 15, 2014. Assoc. Editor: Malisa Sarntinoranont.
- Views Icon Views
- Share Icon Share
- Search Site
Trevizan Pera, D., Freitas Planello, J., Cancino, J., Polikarpov, I., Zucolotto, V., Retto da Silva de Avó, L., Maria Ramos Germano, C., and Gusmão Melo, D. (October 15, 2014). "Effects of 3,5,3′-Triiodothyroacetic Acid, Nanoencapsulated or Not, on Intact and Atrophic Skin in Rats." ASME. J. Nanotechnol. Eng. Med. August 2014; 5(3): 031001. https://doi.org/10.1115/1.4028695
Download citation file: